Foghorn Therapeutics pauses enrollment in cancer study | The Mighty 790 KFGO | KFGO

×

Sign In

Foghorn Therapeutics pauses enrollment in cancer study

Fargo, ND, USA / The Mighty 790 KFGO | KFGO

Thomson Reuters

Apr 24, 2023 | 6:13 AM

(Reuters) – Foghorn Therapeutics Inc said on Monday it has paused enrollment in an early-stage study of the company’s experimental cancer drug due to safety concerns.

(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath)

Multiple ditch fires started by semi hauling ash on northbound I-29

Minnesota State Patrol Lt. pleads guilty to sexual assault

Short term closure of 32nd Ave. 15th St. S set to begin next week

Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports

Grand Forks International Airport control tower to be upgraded

US moves to end job protections for hundreds of health department workers